



DoD Opioid Overdose Education and Naloxone Distribution (OEND) Program: A Guide for Prescribing Naloxone DATE





Learning Objectives



- Understand Department of Defense (DoD) Opioid Overdose Education and Naloxone Distribution (OEND) Program:
 - Use DoD OEND's Quick Reference Guide to understand when and how to prescribe naloxone to your patients
 - Use CarePoint to look up Risk Index for Overdose or Serious Opioid-Induced Respiratory Depression (RIOSORD) scores and Morphine Equivalent Daily Dose (MEDD)
 - Know what key messages to use when discussing naloxone with your patients



Agenda



Naloxone Overview

- OEND Program
- Policy vs. Active Implementation

Review the Quick Reference Guide

- □ Assess/Offer (CarePoint)
- RIOSORD and MEDD Assessment Tools (Case Example)
- Notify & Educate
- Document

Conclusion

- Key Takeaways
- References
- Questions



Discussion Touch Point



Have you prescribed naloxone in the past?

Generation What prompted you to prescribe naloxone?

- Describe your experiences with prescribing naloxone.
 - What are some concerns you have about co-prescribing naloxone to your patients?

OEND Program



- Mission: Reduce opioid-related overdoses and deaths
- Goal: Increase co-prescribing of naloxone

Policy Alignment:

- DoD/VA CPG for Opioid Therapy for Chronic Pain (link)
- DHA-PI 6025.04: Pain Management and Opioid Safety in the Military Health System (MHS) (link)
- DHA-PI 6025.07: Naloxone Prescribing and Dispensing by Pharmacists in Military Treatment Facilities (MTFs) (link)





Where we are now




[Use the Look-Up Tool Dashboard, Opioid Prescriber Monthly Trend Report, and QPP Dashboard Data (all found on CarePoint) to filter by your Market/Site and insert data visualization here.]

Review the Quick Reference Guide



- Developed to help prescribers and pharmacists understand when and how to prescribe naloxone
- Risk Criteria
 - RIOSORD>32
 - □ MEDD>=50
 - Opioid/Benzodiazepine combination use
 - On long-term opioid therapy



Accessing CarePoint, MHSPHP, and the DHA Opioid Registry



- A one-pager with step-by-step instructions will be emailed to participants.
- Look up MHS-direct care RIOSORD scores, MEDD calculations, and opioid-related prescriptions (Rxs) on CarePoint: <u>CarePoint Website</u>







Instructions to Access DHA Opioid Registry



CarePoint Instructions



TUTORIAL



Quick Reference Guide: RIOSORD and MEDD Assessment Tools

- Option to manually calculate two key indicators for whether your patient should be prescribed naloxone:
 - RIOSORD Score > 32
 - □ MEDD >=50

Calculate risk by completing RIOSORD assessment	ratory Depression (RIOSORD		Circle if "YES"	
n the past 6 months, has the patient had a health care visit (out	tpatient, inpatient, or ED) involv	ing:		
Opioid dependence?		-	15	
Chronic hepatitis of cirrhosis?			9	
Bipolar disorder of schizophrenia?			7	
 Chronic pulmonary disease? (e.g., emphysema, chronic bronic 	chitis, asthma, pneumoconiosis,	asbestosis)	5	
Chronic kidney disease with clinical significant renal impairm			5	
 Active traumatic injury, excluding burns? (fracture, dislocation) 		0	4	
 Sleep apnea? 	,	,	3	
Does the patient consume:			3	
 Extended release or long acting (ER/LA) formulation: An ER/L opioid with long and/or variable half-life? (e.g., OxyContin, O levorphanol) 			9	
 Methadone? (Methadone is a long-acting opioid, so also circl 	le for "ER/LA formulation")		9	
 Oxycodone? (If it has an ER/LA formulation [OxyContin], also 	circle for "ER/LA formulation")		3	
A prescription antidepressant? (e.g., fluoxetine, citalopram, v	venlafaxine, amitriptyline)		7	
 A prescription benzodiazepine? (e.g., diazepam, alprazolam) 			4	
s the patient's current maximum prescribed opioid dose: (Use 0	Opioid Daily Dose Conversion Ta	ble below)		
 ≥100 mg morphine equivalents per day? 			16	
 50 – <100 mg morphine equivalents per day? 			9	
 20 – <50 mg morphine equivalents per day? 			5	
n the past 6 months, has the patient:				
 Had 1 or more ED visits? 			11	
Had 1 or more ED visits? Been hospitalized for 1 or more days?			11 8	
	If score > 32, PRESCRIBE			
Been hospitalized for 1 or more days? IOTAL SCORE (add up "YES" response values). Dpioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu type of Opioid (doses in mg/day except where noted) Buprenorphine patch	Itiplying daily dose for each Conversion Factor 12.6	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dpioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu Fype of Opioid (doses in mg/day except where noted) Buprenorphine patch • Buprenorphine tab or film	Itiplying daily dose for each Conversion Factor 12.6 10	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? TOTAL SCORE (add up "YES" response values). Dpioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu type of Opioid (doses in mg/day except where noted) Buprenorphine tab or film Butorphanol (Stadol)	Itiplying daily dose for each Conversion Factor 12.6 10 7	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dpiold Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu type of Opiold (doses in mg/day except where noted) • Buprenorphine patch • Buprenorphine tab or film • Butorphanol (Stadol) • Codeine	ultiplying daily dose for each Conversion Factor 12.6 10 7 0.15	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dipioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu Type of Opioid (doses in mg/day except where noted) Buprenorphine patch Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr)	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dipioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mut Fype of Opioid (doses in mg/day except where noted) Buprenorphine patch Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodone	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dpioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu type of Opioid (doses in mg/day except where noted) Buprenorphine patch Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodone Hydrocodone Hydromorphone	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1 4	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dpioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu Type of Opioid (doses in mg/day except where noted) Bugrenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodone Hydromorphone Meperidine	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dipioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu Type of Opioid (doses in mg/day except where noted) Buprenorphine patch Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodone Hydromorphone Meperidine Methadone	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1 4 0.1	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dipoid Daily Dose Conversion Table: Lafculate Morphine Equivalent Daily Dose (MEDD) by mu type of Opioid (doses in mg/day except where noted) Buprenorphine patch Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodone Hydromorphone Methadone o 1-20 mg/day	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1 4 0.1 4 0.1	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dipiold Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu Type of Opiold (doses in mg/day except where noted) Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodone Hydromorphone Meperidine Methadone 0 1-20 mg/day 0 21-40 mg/day	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1 4 0.1	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dipioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu Type of Opioid (doses in mg/day except where noted) Buprenorphine patch Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodone Hydromorphone Meperidine Methadone o 1-20 mg/day o 21-40 mg/day o 41-60 mg/day	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1 4 0.1 4 8	opioid by the co	8 nversion *	
Been hospitalized for 1 or more days? OTAL SCORE (add up "YES" response values). Dipiold Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu Type of Opiold (doses in mg/day except where noted) Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodone Hydromorphone Meperidine Methadone 0 1-20 mg/day 0 21-40 mg/day	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1 4 0.1 4 8 10	opioid by the co	8 nversion *	
 Been hospitalized for 1 or more days? TOTAL SCORE (add up "YES" response values). Dipioid Daily Dose Conversion Table: calculate Morphine Equivalent Daily Dose (MEDD) by mu type of Opioid (doses in mg/day except where noted) Buprenorphine patch Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodne Hydrocorphone Meperidine Meperidine 1-20 mg/day 21-40 mg/day 21-60 mg/day 21-61 mg/day 2 1-80 mg/day Morphine 	Altiplying daily dose for each 12.6 10 7 0.15 2.4 1 4 0.1 4 10 12	opioid by the co	8 nversion *	
 Been hospitalized for 1 or more days? TOTAL SCORE (add up "YES" response values). Opioid Daily Dose Conversion Table: Calculate Morphine Equivalent Daily Dose (MEDD) by mu Type of Opioid (doses in mg/day except where noted) Buprenorphine patch Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodone Hydrocodone Methadone o 1-20 mg/day o 21-40 mg/day o 21-40 mg/day o 21-80 mg/day 	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1 4 0.1 4 8 10 12 1	opioid by the co	8 nversion *	
 Been hospitalized for 1 or more days? TOTAL SCORE (add up "YES" response values). Dipioid Daily Dose Conversion Table: calculate Morphine Equivalent Daily Dose (MEDD) by mu type of Opioid (doses in mg/day except where noted) Buprenorphine patch Buprenorphine tab or film Butorphanol (Stadol) Codeine Fentanyl transdermal (in mcg/hr) Hydrocodne Hydrocorphone Meperidine Meperidine 1-20 mg/day 21-40 mg/day 21-60 mg/day 21-61 mg/day 2 1-80 mg/day Morphine 	Itiplying daily dose for each Conversion Factor 12.6 10 7 0.15 2.4 1 4 0.1 4 4 0.1 4 8 10 12 12 1 1.5	opioid by the co	8	

Quick Reference Guide





Case Example



Patient John Smith comes in for an outpatient visit regarding his chronic lower back pain.

He has been on hydrocodone for about a year. He requests a renewal of his prescription. You have not yet established an account in CarePoint but want to determine if you should prescribe naloxone.

He currently has a prescription for citalopram for mild depression.

His current average daily opioid dosage is 52 mg morphine equivalent dosage per day. The patient had one emergency department visit 4 months ago and was hospitalized for 3 days.



Based on the information provided, should you prescribe naloxone?

\bigcirc	
2	

Risk Index for Overdose or Serious Opioid-Induced Respiratory Depression (RIOSORD): Calculate risk by completing RIOSORD assessment	Circle if "YES
In the past 6 months, has the patient had a health care visit (outpatient, inpatient, or ED) involving:	
Opioid dependence?	15
Chronic hepatitis of cirrhosis?	9
Bipolar disorder of schizophrenia?	7
 Chronic pulmonary disease? (e.g., emphysema, chronic bronchitis, asthma, pneumoconiosis, asbestosis) 	5
 Chronic kidney disease with clinical significant renal impairment? 	5
 Active traumatic injury, excluding burns? (fracture, dislocation, contusion, laceration, wound) 	4
Sleep apnea?	3
Does the patient consume:	
 <u>Extended release or long acting (ER/LA) formulation</u>: An ER/LA formulation of any prescription opioid or opioid with long and/or variable half-life? (e.g., OxyContin, Oramorph-SR, methadone, fentanyl patch, levorphanol) 	9
 Methadone? (Methadone is a long-acting opioid, so also circle for "ER/LA formulation") 	9
 Oxycodone? (If it has an ER/LA formulation [OxyContin], also circle for "ER/LA formulation") 	3
 A prescription antidepressant? (e.g., fluoxetine, citalopram, venlafaxine, amitriptyline) 	7
 A prescription benzodiazepine? (e.g., diazepam, alprazolam) 	4
s the patient's current maximum prescribed opioid dose: (Use Opioid Daily Dose Conversion Table below)	
 >100 mg morphine equivalents per day? 	16
 50-100 mg morphine equivalents per day? 	9
20-50 mg morphine equivalents per day?	5
n the past 6 months, has the patient:	
Had 1 or more ED visits?	11
Been hospitalized for 1 or more days?	8
TOTAL SCORE (add up "YES" response values). If score > 32, PRESCRIBE NALOXONE >	35

Quick Reference Guide: Notify & Educate



DHA-PI 6025.07 includes a brochure on opioid safety and naloxone administration that you can distribute to patients and their caregivers. This brochure is currently being finalized and will soon be available online at: <u>health.mil/opioidsafety</u>

SAVE A LI	FE: HOW TO PREVENT OPIOID POISONING DEATHS	IN CASE OF OPIOID POISONING (OVERDOSE)
What are oploids? Opioids are drugs that are often used in pain management. Everyone who takes opioids is at risk for opioid opisoning (overdose), even if	uide for Patients and Caregivers Common Opioids Include: GENERIC NAME Bydescedee Vicesi, Incert, Infah, Noro, Zolydfo	What is naloxone? Naloxone (Narcan) is a temporary antidote for an opioid overdose. Should an overdose occur, naloxone will temporarily restore your breathing. Because you are passed out during an overdose, somence see will need to administer this medication. Be sure to call your family members and friends where you keep your naloxone, and teach them how to use it.
taken as prescribed, and should take appropriate precautions.	Opcodes Percoce, Op/Costs, Rescoden, Percodes Morphine MSCostn, Alchad, Turbod, Alwaza Codetine Tylenni with Codene, (Co., Vjecol 83 Fettanyl Durages, (Long) Opfonorphone Disudd Opgendrame Disudd Opgendrame Disudd Methadom Denrent Methadom Disubylen, Methadose	1 Check responsiveness Look for any of the following: • <
Expending in the set of the		2 Call 911 and give naioxone If no reaction in 2-3 minutes, give second naioxone dose in the other rostni. (melication comes in two packs) This nasal spray needs no assembly and can be sprayed up one nostri by pushing the plunger.
		3 Follow 911 dispatcher instructions Dispatcher may provide instructions for rescue breathing and/ or CPR.
Tell them that you take opioids Ask them to help you take opioids safely Tell them where you keep the naloxone kit and how	You may feed the loss settlenared symptoms You may every the help you start taking opticals again after an optical-free break	>> Stay with person until help arrives
ADDITIONAL RESOURCES Local Emergency Sentces: 911 For other patient and caregiver resources, please vtat: health	n mil/opicidaniky	For more information about accessing naloxone, talk to your pharmacist or provider.

How to Talk to Patients and Caregivers about Naloxone



Example Scenario (Role Play)

- Key messages/talking points:
 - Opioid use disorder is a pain management issue
 - Naloxone is a lifesaving precaution; it does not lead to increased drug abuse
 - When managing pain, use opioids as prescribed



Video – How to use the VA Naloxone Nasal Spray (from the Veterans Health Administration)





































Discussion Touch Point




- What did the pharmacist do that was useful in addressing the patient's concerns?
- What strategies would you have used to address them?
- Have you discussed naloxone with any of your patients?
 - □ Were they receptive?
 - □ What were some barriers you encountered?

Myths and Facts












- False: Even if your patient does not abuse their medication, accidental overdoses can happen and naloxone is an important safety precaution that helps keep them and their loved ones safe.
 - □ While your patient may not seem like they are at risk for an overdose, having a RIOSORD > 32 indicates that they may have a combination of smaller risk factors that puts them at a greater overall risk.








- Truth: Studies report that naloxone does not encourage drug use. In some cases, naloxone has been shown to decrease drug use. Naloxone blocks the effects of opioids and can produce unpleasant withdrawal symptoms.
 - Following a successful overdose reversal, a patient can access additional treatment options that they may not have considered previously.








- False: Naloxone comes in several forms. We generally recommend the intranasal form (e.g., Narcan) which allows people to spray naloxone into the patient's nostrils. Distribute the "Naloxone Administration" brochure to walk through the process with the patient.
 - We recommend administering a second dose if the patient is not breathing 2-3 minutes after the first dose; or responds to the first dose but stops breathing again. Naloxone wears off after 30 to 60 minutes.








False: The policy for administering naloxone applies to the entire MHS. MTF Commanders should ensure that their MTF implements this policy and service members should not encounter any issues for having a naloxone prescription.







True: DHA-PI 6025.07 for "Naloxone Prescribing and Dispensing by Pharmacists in Military Treatment Facilities" authorizes pharmacists to dispense naloxone upon patient request.



Additional Resources



- The OEND page provides additional resources for patients, caregivers, prescribers, and pharmacists, such as:
 - □ Training Resources
 - CarePoint Instructions
 - The Quick Reference Guide

health.mil/oend



Opioid Prescriber Monthly Trend Report and Patient Look-Up Tool Dashboard



- The Opioid Prescriber Monthly Trend Report allows you to monitor opioid and naloxone prescribing trends on the MTF-, clinic-, and prescriber-level (provider-focused). <u>https://bitab.health.mil/#/views/OpioidPrescriberMonthlyTre</u> <u>ndReport/PrescriberTrendReport</u>
- The Patient Look-Up Tool Dashboard allows you to look at opioid and naloxone dispensing trends on the MTF- and pharmacy-level (pharmacist focused).

https://bitab.health.mil/#/views/PatientLookupToolDashboar d/PhamacyDetailedView

Key Takeaways



- Prescribing naloxone is standard best practice
- The Quick Reference Guide helps determine when and how to prescribe naloxone:
 - Assess if your patients are at risk for an overdose
 - Educate your patients (and their family member/support person when possible) about opioid safety and naloxone administration
 - Document elevated risk indications and naloxone discussion and prescription in your patient's electronic health record

Any patient that meets the following risk criteria should be prescribed naloxone:

- RIOSORD>32
- □ MEDD>=50
- **Opioid/Benzodiazepine combination use**
- On long-term opioid therapy





- Talking to patients about naloxone:
 - Use key messages
 - Educate both patients and their caregivers
 - Be prepared to answer questions
- Share resources with other members of your healthcare team
- Work with your team to develop a day-to-day action plan for educating and co-prescribing naloxone to patients

For more information, visit <u>health.mil/oend</u>





- CVSHealth. (August 2017). Myths and facts about naloxone. Retrieved from <u>https://cvshealth.com/thought-leadership/myths-and-facts-about-naloxone</u>
- Defense Health Agency. (June 19, 2018). Naloxone Prescribing and Dispensing by Pharmacists in Medical Treatment Facilities. (DHA-PI 6025.07). Retrieved from <u>https://health.mil/Reference-</u> <u>Center/Policies/2018/06/19/DHA-PI-6025-07-Naloxone-in-the-MTFs</u>
- Department of Veterans Affairs (2017). VA/DoD clinical practice guideline for opioid therapy for chronic pain. Retrieved from <u>https://www.healthquality.va.gov/guidelines/Pain/cot/VADoDOTCPG022717.pdf</u>
- Murphy, L., Babaei-Rad, R., Buna, D., Isaac, P., Murphy, A., Ng, K., ... & Sproule, B. (2018). Guidance on opioid tapering in the context of chronic pain: Evidence, practical advice and frequently asked questions. *Canadian Pharmacists Journal/Revue des Pharmaciens du Canada*, 151(2), 114-120. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843113/
- Naloxoneinfo.org. (n.d.). Naloxone: Frequently Asked Questions. Retrieved from <u>http://naloxoneinfo.org/sites/default/files/Frequently Asked Questions-Naloxone_EN.pdf</u>
- Seal, K. H., Thawley, R., Gee, L., Bamberger, J., Kral, A. H., Ciccarone, D., Downing, M., ... Edlin, B. R. (2014). Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. *Journal of urban health : Bulletin of the New York Academy of Medicine*, 82(2), 303-11.



Questions?